Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: Post hoc safety analysis from HELIOS-B

Vyndaqel (tafamidis meglumine) - Pfizer

Amvuttra (vutrisiran) - Alnylam

SK Schwarting1; K Tsujita2; BW Sperry3; JD Gillmore4; MA Urey5; JP Costabel6; T Ripoll7; H Zheng8; S Eraly8; P Reant9

May 11, 2026